LEQEMBI (lecanemab) Patient Assistance Program
Don’t let the high cost of brand specialty Alzheimer’s therapy stand between you and the treatment you need. We help eligible patients access Leqembi (lecanemab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Leqembi (lecanemab) is FDA-approved for the treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage of disease whose presence of amyloid beta pathology has been confirmed. It is given as an intravenous infusion every two weeks (a subcutaneous maintenance form is also available).
- Without assistance, Leqembi costs approximately $26,500 per year at the wholesale acquisition cost, with per-infusion costs commonly $1,000+ depending on weight. A subcutaneous maintenance form is also available.
- Through AffordMyPrescriptions, qualifying patients can access Leqembi for a flat $69.95 per month — our advocacy team manages the entire enrollment, infusions, and renewal process.
- There is no biosimilar version of Leqembi available in the U.S. as of 2026.
What Is Leqembi Prescription Assistance Program?
The Leqembi Prescription Assistance Program is a manufacturer-sponsored initiative that provides Leqembi at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for early Alzheimer’s disease patients who are uninsured or underinsured, as well as Medicare beneficiaries (Medicare typically covers Leqembi for eligible patients meeting CMS criteria).
Navigating the program on your own means dealing with eligibility verification, neurology coordination, amyloid-PET or CSF testing documentation, ApoE4 genotype testing documentation, infusion-center scheduling, MRI monitoring schedules for ARIA, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion-schedule coordination and annual re-certification — so you focus on your care, not paperwork.
Pharmacy Price Comparison
- Without assistance, Leqembi costs approximately $26,500/year at WAC, with per-infusion costs commonly $1,000+ at retail/specialty pricing. Pharmacy discount coupons are not a meaningful tool for IV therapy. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Per IV infusion (~70 kg) | ~$1,030.00 | Save ~$960/dose |
| Per IV infusion (~100 kg) | ~$1,470.00 | Save ~$1,400/dose |
| Bi-weekly schedule | ~$2,200/mo | Save ~$2,130/mo |
| Annual cost (WAC) | ~$26,500/yr | Save ~$25,500/yr |
| Required MRI monitoring | Add’l cost | Coordinated by us |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Leqembi Prescription Program?
The Patient Assistance Program is free to apply for and provides Leqembi at little or no medication cost if approved. But the process involves detailed applications, neurology coordination, amyloid pathology confirmation (PET scan or CSF testing), ApoE4 genotype testing, MRI monitoring schedules for ARIA (amyloid-related imaging abnormalities), infusion scheduling, and ongoing renewal management. Our $69.95/month service covers full advocacy: applications, doctor coordination, testing documentation, infusion scheduling, MRI coordination, and annual re-enrollment.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Leqembi:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $1,000–$1,500 per infusion per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Leqembi assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Leqembi Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Leqembi :
Leqembi (lecanemab) is an intravenous (or subcutaneous maintenance) anti-amyloid monoclonal antibody used to treat early Alzheimer’s disease — specifically the mild cognitive impairment (MCI) and mild dementia stages — in patients whose amyloid beta pathology has been confirmed by amyloid-PET imaging or cerebrospinal fluid (CSF) testing. It is one of the first approved disease-modifying therapies for Alzheimer’s disease.
How Leqembi Works:
Leqembi is a monoclonal antibody designed to target and clear amyloid beta protein, which forms toxic plaques in the brains of Alzheimer’s patients. It specifically binds to soluble protofibrils and aggregated forms of the protein to reduce plaque burden and slow clinical cognitive decline. By promoting the clearance of these substances, the medication aims to address the underlying neurodegeneration associated with early Alzheimer’s disease.
Form and use:
Initial treatment involves a one-hour IV infusion administered every two weeks at a dosage of 10 mg/kg. After an 18-month induction period, eligible patients have the option to transition to a weekly subcutaneous maintenance injection. Throughout the treatment process, patients must undergo regular brain MRIs to monitor for specific imaging abnormalities related to amyloid clearance.
Generic availability:
As of 2026, there are no biosimilar versions of Leqembi available in the United States. Other anti-amyloid therapies, such as Kisunla (donanemab), are FDA-approved and may be considered as alternatives. The choice between these branded biologics depends on factors like infusion logistics, individual risk profiles, and how well a patient tolerates the medication.
Warnings:
Leqembi carries a boxed warning for Amyloid-Related Imaging Abnormalities (ARIA), which can involve brain swelling or microhemorrhages. Patients are encouraged to undergo ApoE4 genotype testing before starting therapy, as certain genetic profiles carry a higher risk for these complications. Other potential risks include infusion reactions and increased bleeding risks for those on blood thinners, necessitating close monitoring for symptoms like headaches or confusion.
FAQ (Frequently Asked Questions)
How Much Does Leqembi Cost Without Insurance?
Leqembi costs approximately $26,500/year at WAC. Per-infusion costs are weight-based and typically $1,000+ at retail/specialty pricing. Through AffordMyPrescriptions, qualifying patients receive Leqembi at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Leqembi Given?
Leqembi is given as a 1-hour IV infusion every two weeks at 10 mg/kg during the induction phase. After 18 months of bi-weekly IV induction, eligible patients can transition to a subcutaneous maintenance formulation administered weekly at home. Treatment requires baseline and ongoing brain MRIs to monitor for ARIA.
What Is ARIA And Why Is MRI Monitoring Required?
ARIA stands for amyloid-related imaging abnormalities. ARIA-E refers to brain edema, and ARIA-H refers to small hemorrhages or hemosiderin deposits in the brain. Both can occur with anti-amyloid therapies and are usually asymptomatic, but can sometimes cause headaches, confusion, or seizures. ApoE4 homozygotes are at higher risk. Regular brain MRIs (at baseline and at scheduled timepoints during therapy) are required to detect and manage ARIA early.
Can I Get Leqembi Through Medicare?
Yes. Medicare typically covers Leqembi for patients meeting CMS coverage criteria (including registry participation), and our advocates can help navigate Medicare coverage rules. The manufacturer’s commercial copay program is for commercially insured patients only — but the underlying PAP supports Medicare beneficiaries who face significant out-of-pocket costs.
Do I Need Tests Before Starting Leqembi?
Yes. Before starting Leqembi, you must have confirmation of amyloid beta pathology — through amyloid-PET imaging or cerebrospinal fluid (CSF) testing. ApoE4 genotype testing is also recommended because ApoE4 homozygotes have a higher risk of ARIA. A baseline brain MRI is also required, and ongoing MRIs are scheduled during therapy to monitor for ARIA.
What If My Application Is Denied?
If your initial application is denied, we explore alternative savings paths on your behalf — including the manufacturer’s copay assistance program if you have commercial insurance, independent foundations such as the PAN Foundation or HealthWell Foundation, the Alzheimer’s Association, or asking your neurology team whether donanemab (Kisunla) on a different cost path would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Leqembi, our team may be able to help you access assistance programs designed to make brand specialty Alzheimer’s therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.